Stay updated on Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.

Latest updates to the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference10%

- Check26 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.2%

- Check40 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2 and the Back to Top control was removed; overall content remains effectively the same.SummaryDifference0.6%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.6%

- Check54 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and country listings.SummaryDifference36%

- Check69 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%

Stay in the know with updates to Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.